Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Supergut, the only nutrition brand clinically-validated to improve digestive health and curb cravings, is rolling out ...

For everything from GLP-1 and cancer costs to provider networks, one employer association has strategies — and they don't ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Five years ago, Viking Therapeutics (NASDAQ: VKTX) was an unknown, clinical-stage biotech. It hardly stood out in a sea of small drugmakers, and most of those never end up producing the kinds of ...

Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger ...

Valued at $35.3 billion by market cap, San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications for ...

Amgen has downgraded Amgen from buy to hold saying that the potential for obesity asset MariTide is already included in the ...

As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or ...

Dear Editor, While GLP-1 medications have proven successful in helping people lose weight, some precautions also need to be ...

It's been a very difficult year for Walgreens Boots Alliance (NASDAQ: WBA), which has seen its stock lose two-thirds of its ...

The future of the weight loss market might not revolve around GLP-1 drugs.